Core Viewpoint - The company and its subsidiary Hangzhou Danwei have recently obtained multiple medical device product registration certificates, enhancing their product offerings and market reach [1] Domestic Developments - Hangzhou Danwei's Mycoplasma pneumoniae nucleic acid detection kit (fluorescent PCR method) has been registered, with a validity period until January 18, 2031 [1] International Developments - The company has received registration certificates for several products, including the creatine kinase isoenzyme detection kit, in Brazil and the European Union, with varying validity periods [1] Product Portfolio Enhancement - The recent certifications supplement the company's pneumonia detection product series and improve the layout of time-resolved fluorescence immunochromatography products, expanding the sales regions [1] Sales Performance Outlook - Actual sales performance from these newly registered products cannot be predicted at this time [1]

Core Viewpoint - The company, Shengxiang Biology, announced on October 31 that several of its nucleic acid testing kits for respiratory viruses have received medical device registration certificates from the National Medical Products Administration of China, indicating regulatory approval for these products [1] Product Approval - The approved products include nucleic acid testing kits for respiratory syncytial virus, influenza A and B viruses, adenovirus, and mycoplasma pneumoniae, all utilizing fluorescent PCR methods [1] - The approval of these products is expected to enhance the company's market presence and product offerings in the diagnostic sector [1] Future Performance Uncertainty - The future performance of these products will be influenced by multiple factors, including market expansion efforts, brand influence, and actual market demand [1] - The company has indicated that the sales and profit contributions from these products remain uncertain, making it difficult to predict their specific impact on future performance [1]